LON:SN

Smith & Nephew - SN Share Forecast, Price & News

GBX 1,091.50

+19.50 (+1.82%)

(As of 12/7/2022 12:00 AM ET)

Add

Compare

Today's Range: 1,074
▼
1,095
50-Day Range: 984.60
▼
1,103.50
52-Week Range: 959.20
▼
1,357.50

Volume: 2.20 million shs
Average Volume: 343,671 shs
Market Capitalization: £9.50 billion

P/E Ratio: 2,322.34
Dividend Yield: 2.89%
Price Target: GBX 1,408.60

Smith & Nephew MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 29.1% Upside
GBX 1,408.60 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: -1.95
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
£2.01 M Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

3.4

Analyst's Opinion

Consensus Rating
Smith & Nephew has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 1,408.60, Smith & Nephew has a forecasted upside of 29.1% from its current price of GBX 1,091.50.
Amount of Analyst Coverage
Smith & Nephew has only been the subject of 3 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for SN.

0.8

Dividend Strength

Dividend Yield
Smith & Nephew pays a meaningful dividend of 2.89%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Smith & Nephew does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Smith & Nephew is 6,595.74%. Payout ratios above 75% are not desirable because they may not be sustainable.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Smith & Nephew has received a 45.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Wound dressings", "Treatment of wounds and ulcers (D03)", and "Artificial joints" products. See details.
Environmental Sustainability
The Environmental Impact score for Smith & Nephew is -1.95.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Smith & Nephew this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for SN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Smith & Nephew to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Smith & Nephew insiders have sold more of their company's stock than they have bought. Specifically, they have bought GBX 0 in company stock and sold £20,109.27 in company stock.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Smith & Nephew is 2,322.34, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 126.30.
Price to Earnings Ratio vs. Sector
The P/E ratio of Smith & Nephew is 2,322.34, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 128.44.
Price to Earnings Growth Ratio
Smith & Nephew has a PEG Ratio of 3.99. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Smith & Nephew has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Smith & Nephew (LON:SN) Stock

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Receive SN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

SN Stock News Headlines

December 8, 2022 | finance.yahoo.com

With 88% ownership of the shares, Smith & Nephew plc (LON:SN.) is heavily dominated by institutional owners

November 29, 2022 | msn.com

Will Smith Revealed His 9-Year-Old Nephew’s Eye-Opening Reaction After Oscars Slap

November 24, 2022 | finance.yahoo.com

Great news for Smith & Nephew plc (LON:SN.): Insiders acquired stock in large numbers last year

November 9, 2022 | americanbankingnews.com

Smith & Nephew (LON:SN) Stock Rating Reaffirmed by Berenberg Bank

November 1, 2022 | finance.yahoo.com

Smith+Nephew expands procedural innovation with introduction of JOURNEY™ II ROX™ Total Knee Solution

October 18, 2022 | finance.yahoo.com

Investors in Smith & Nephew (LON:SN.) have unfortunately lost 36% over the last three years

October 12, 2022 | msn.com

Smith & Nephew site could be developed sooner as part of government's Investment Zone plans

September 26, 2022 | finance.yahoo.com

GSK Taps Burberry Executive As CFO

September 26, 2022 | finance.yahoo.com

Smith+Nephew first to market with revision knee indication on robotics platform

September 21, 2022 | finance.yahoo.com

Smith+Nephew Academy expands global access to professional medical education through virtual reality and other advanced simulation technologies

September 19, 2022 | finance.yahoo.com

Smith+Nephew launches OR3O™ Dual Mobility System in Japan for use in primary and revision hip arthroplasty

September 8, 2022 | thestreet.com

Smith & Nephew Becomes Pharma Family Factor

September 7, 2022 | finance.yahoo.com

Smith & Nephew plc (SN.L)

August 28, 2022 | fool.co.uk

2 FTSE 100 stocks I’m buying for their defensive qualities and global portfolios!

July 29, 2022 | msn.com

MARKET REPORT: Medical implant and prosthetics maker Smith & Nephew leads FTSE100 lower on bumper day of results in Square Mile

July 28, 2022 | finance.yahoo.com

Smith & Nephew Shares Fall On Lower Margins As Cost Headwinds Hit Q2 Profit

July 28, 2022 | nasdaq.com

UK's Smith+Nephew warns on margins as inflation, supply risks weigh

July 28, 2022 | msn.com

UK's Smith+Nephew shares dive 10% after profit margin warning

July 12, 2022 | finanznachrichten.de

Smith & Nephew plc: Smith+Nephew launches Clinical Support App to help reduce practice variation in wound care

July 12, 2022 | finance.yahoo.com

Smith+Nephew launches Clinical Support App to help reduce practice variation in wound care

July 6, 2022 | uk.finance.yahoo.com

Do analysts think that Smith amp; Nephew is a buy, hold or sell?

June 28, 2022 | msn.com

Smith+Nephew opens a manufacturing facility in Malaysia with an investment worth over US$100mil

June 21, 2022 | fool.co.uk

2 FTSE 100 stocks I’d buy to build wealth in the long run

June 15, 2022 | msn.com

Labour calls for new hi-tech hub at Smith & Nephew site in Hessle Road

June 15, 2022 | uk.finance.yahoo.com

How has the Smith amp; Nephew share price performed over the past year?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

SN Company Calendar

Ex-Dividend for 10/26 Dividend: 9/29/2022
Dividend Payable: 10/26/2022
Today: 12/08/2022
Next Earnings (Estimated): 2/21/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Medical Appliances & Equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:SN
CUSIP: N/A
CIK: N/A
Web: www.smith-nephew.com
Phone: +44-20-74017646
Fax: N/A
Employees: 18,369
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: GBX 1,408.60
High Stock Price Forecast: GBX 1,500
Low Stock Price Forecast: GBX 1,243
Forecasted Upside/Downside: +29.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 2,322.34
Forward P/E Ratio: 1,550.65
P/E Growth: 3.99
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 53.62
Current Ratio: 1.78
Quick Ratio: 0.84

Sales & Book Value

Annual Sales: £5.21 billion
Price / Sales: 1.82
Cash Flow: GBX 59.31 per share
Price / Cash Flow: 18.40
Book Value: GBX 615.70 per share
Price / Book: 1.77

Miscellaneous

Outstanding Shares: 870,696,000
Free Float: N/A
Market Cap: £9.50 billion
Optionable: Optionable
Beta: N/A

Key Executives

Ms. Anne-Francoise Nesmes (Age 50)
CFO & Exec. Director
Comp: $1.71M

Dr. Deepak S. Nath Ph.D. (Age 49)
CEO & Director

Mr. Paul Connolly (Age 54)
Pres of Global Operations

Mr. Andrew Swift
VP of Investor Relations

Ms. Helen Barraclough (Age 43)
Group Gen. Counsel, Company Sec. & Director

Ms. Alison Parkes (Age 50)
Chief Compliance Officer

Mr. Joe Metzger
Sr. VP of Marketing Services & Communications

Ms. Elga Lohler (Age 54)
Chief HR Officer

Mr. Philip G. Cowdy (Age 55)
Chief Bus. Devel. & Corp. Affairs Officer

Mr. Bradley Cannon (Age 54)
Pres of Orthopaedics, Sports Medicine & ENT and Americas

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SN Stock - Frequently Asked Questions

Should I buy or sell Smith & Nephew stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SN shares.
View SN analyst ratings or view top-rated stocks.
What is Smith & Nephew's stock price forecast for 2023?: 5 Wall Street research analysts have issued 1 year price objectives for Smith & Nephew's stock. Their SN share price forecasts range from GBX 1,243 to GBX 1,500. On average, they expect the company's stock price to reach GBX 1,408.60 in the next twelve months. This suggests a possible upside of 29.1% from the stock's current price.
View analysts price targets for SN or view top-rated stocks among Wall Street analysts.
How have SN shares performed in 2022?: Smith & Nephew's stock was trading at GBX 1,293.50 on January 1st, 2022. Since then, SN stock has decreased by 15.6% and is now trading at GBX 1,091.50.
View the best growth stocks for 2022 here.
When is Smith & Nephew's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our SN earnings forecast.
How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?: Smith & Nephew declared a dividend on Thursday, July 28th. Stockholders of record on Thursday, September 29th will be given a dividend of GBX 0.14 per share on Wednesday, October 26th. This represents a yield of 0.99%. The ex-dividend date of this dividend is Thursday, September 29th. The official announcement can be viewed at this link.
Read our dividend analysis for SN.
Is Smith & Nephew a good dividend stock?: Smith & Nephew (LON:SN) pays an annual dividend of GBX 31 per share and currently has a dividend yield of 2.89%. The dividend payout ratio is 6,595.74%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for SN.

What other stocks do shareholders of Smith & Nephew own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Imperial Brands (IMB), Smith & Nephew (SNN), Alexion Pharmaceuticals (ALXN), Barclays (BARC), GSK (GSK), Diageo (DGE), Standard Chartered (STAN), Unilever (ULVR), British American Tobacco (BATS) and BHP Group (BHP).
What is Smith & Nephew's stock symbol?: Smith & Nephew trades on the London Stock Exchange (LON) under the ticker symbol "SN."
How do I buy shares of Smith & Nephew?: Shares of SN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Smith & Nephew's stock price today?: One share of SN stock can currently be purchased for approximately GBX 1,091.50.
How much money does Smith & Nephew make?: Smith & Nephew (LON:SN) has a market capitalization of £9.50 billion and generates £5.21 billion in revenue each year.
How many employees does Smith & Nephew have?: The company employs 18,369 workers across the globe.
How can I contact Smith & Nephew?: Smith & Nephew's mailing address is 15 Adam Street, LONDON, WC2N 6LA, United Kingdom. The official website for the company is www.smith-nephew.com. The company can be reached via phone at +44-20-74017646.

This page (LON:SN) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Smith & Nephew - SN Share Forecast, Price & News

Smith & Nephew MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Smith & Nephew (LON:SN) Stock

SN Stock News Headlines

SN Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SN Stock - Frequently Asked Questions

Overall MarketRank^™